To test this hypothesis, we analyzed the effects of LINC00883/miR-136/NEK1 on glioma cell resistance to temozolomide (TMZ) and tumorigenicity in the in vitro and in vivo settings. The gene discussed is NEK1; the disease is central nervous system cancer.